---
title: The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis
nct_id: NCT04287205
overall_status: COMPLETED
phase: NA
sponsor: Kanuni Sultan Suleyman Training and Research Hospital
study_type: INTERVENTIONAL
primary_condition: Endometriosis
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04287205.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04287205"
ct_last_update_post_date: 2020-03-18
last_seen_at: "2026-05-12T07:07:10.024Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis

**NCT ID:** [NCT04287205](https://clinicaltrials.gov/study/NCT04287205)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 79
- **Lead Sponsor:** Kanuni Sultan Suleyman Training and Research Hospital
- **Conditions:** Endometriosis, Sexual Dysfunction
- **Start Date:** 2019-04-20
- **Completion Date:** 2020-03-03
- **CT.gov Last Update:** 2020-03-18

## Brief Summary

This study aimed to assess the effects of dydrogesterone on sexual function in women with endometriosis using Female Function Sexual Index (FSFI).

## Detailed Description

Sexual dysfunction is an important outcome for patients with endometriosis. In this study, we compare the fsfi (female sexual function index) questions and the scores before and after dydrogesterone treatment in patients with endometriosis. We aim to measure the effect of dydrogesterone in patients with endometriosis.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* no history of malignancies,
* normal findings at gynecological examinations and transvaginal ultrasonography
* normal uterine size, normal cervical smear results,
* patients not use any contraception methods in the last 6 months

Exclusion Criteria:

* with a history of systemic and/or psychiatric diseases,
* gynecological pathologies (myoma uteri, endometriosis, uterine anomalies, existing genital infections)
* pelvic organ prolapse
* pelvic surgeries
```

## Arms

- **women with endometriosis** (EXPERIMENTAL)

## Interventions

- **Dydrogesterone** (DRUG) — 79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment

## Primary Outcomes

- **The Effect of Dydrogesterone on Sexual Function** _(time frame: 6 months)_ — In this study, we compare the fsfi(female sexual function index) questions and the scores before and after dihydrogestreone treatment in patients with endometriosis. We aim to measure the effect of dihydrogesterone in patients with endometriosis.

## Secondary Outcomes

- **The Effect of Dydrogesterone on Sexual Function in women with endometrioma** _(time frame: 6 months)_

## Locations (1)

- Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pinar yalcin bahat|istanbul|i̇̇stanbul|turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04287205.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04287205*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*